Myriad Genetic “announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad’s oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombination deficiency testing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Myriad Genetics signs agreement to acquire certain assets from Intermountain
- Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
- Mesa Labs appoints Mark Capone to board of directors
- Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference